RE:RE:RE:Results Pretty certain Sue and her team knew where the numbers would fall before they submitted the initial app for the Nasdaq listing.
Keep in mind that included in the Year to Date loss of 18M is:
5M of R&D which is required to be expensed under the accounting framework applied here (IFRS). In fact this work ultimately results in securing the patents - i.e. the value of the company. In real world terms, this should be on the balance sheet for the most part.
7.5M of stock based compensation which is also required to be expensed under IFRS but in fact is a non cash item derived using an option pricing model.
To say nothing of the fact we are pre revenue as everyone knows.
Rest easy, no surprises here at all.